Use of a peptide

• US 5,631,224 A
• Filed: 10/13/1994
• Issued: 05/20/1997
• Est. Priority Date: 03/19/1992
• Status: Expired

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Efendic, Suad, Gutniak, Mark, Kirk, Ole
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Prickril, Benet
• Application Number:
  US08/295,913
• Time in Patent Office: 950 Days
• Field of Search: 514/12, 514/2, 530/308
• US Class Current: 514/6.9
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/175 having the group , >N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/64 Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The invention employs GLP-1(7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.

Claims

1. A method of treating diabetes which method comprises administering an effective amount of GLP-1(7-36)amide, GLP-1(7-37), or a fragment thereof which retains GLP-1(7-37)activity, to a patient in need of such a treatment in a regimen which additionally comprises treatment with an oral hypoglycaemic agent, wherein said hypoglycaemic agent is characterized as acting on an ATP-dependent potassium channel.

2. The method of claim 1 in which GLP-1(7-37) or GLP-1(7-36)amide is administered.

3. The method of claim 1 in which the oral hypoglycaemic agent is a blocker of the ATP-dependent potassium channel on β

-cells.

4. The method of claim 1 in which the oral hypoglycaemic agent is a sulfonylurea.

5. The method of claim 1 in which the oral hypoglycaemic agent is (S)-(+)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid.

6. The method of claim 1 in which the oral hypoglycaemic agent is a biguanide.

7. The method of claim 6 in which the oral hypoglycaemic is metformin.

8. The method of claim 2 in which the oral hypoglycaemic agent is a blocker of the ATP-dependent potassium channel on β

-cells.

9. The method of claim 2 in which the oral hypoglycaemic agent is a sulfonylurea.

10. The method of claim 2 in which the oral hypoglycaemic agent is (S)-(+)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid.

11. The method of claim 2 in which the oral hypoglycaemic agent is a biguanide.

12. The method of claim 11 in which the oral hypoglycaemic is metformin.